arimoclomol
Treatment for Niemann-Pick Disease, type C
Orphazyme Announces FDA Acceptance and Priority Review of New Drug Application for Arimoclomol for Niemann-Pick Disease Type C
Copenhagen, Denmark, September 16, 2020 – Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company’s New Drug Application (NDA) for arimoclomol for the treatment of NPC.
The FDA grants Priority Review to applications for potential therapies that, if approved, could offer a significant improvement in safety or effectiveness, diagnosis, or prevention of serious conditions. This designation shortens the review period from the standard 10 months to six months from the acceptance of the NDA. The FDA has set a target action date of March 17, 2021 under the Prescription Drug User Fee Act (PDUFA) and has indicated that it does not currently plan to hold an advisory committee meeting to discuss the application.
Kim Stratton, Chief Executive Officer, Orphazyme, said, “The filing acceptance marks a significant milestone in our journey towards our first potential approval of arimoclomol for NPC, a devastating and often fatal disease for which there is no approved therapy in the U.S. We look forward to collaborating with the FDA as they complete their review of this NDA to address the unmet medical need in NPC, and meanwhile are working to expand our U.S. activities in preparation for potential commercial availability next year.”
“Acceptance of the arimoclomol filing by the FDA is another major step forward in the effort to bring a treatment to people affected by Niemann-Pick disease Type C and is a reflection of the commitment of the entire community coming together to support promising research,” said Joslyn Crowe, Executive Director of the National Niemann-Pick Disease Foundation.
Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for arimoclomol in NPC in H2 2020.
Source: Orphazyme A/S
Posted: September 2020
Related Articles
More News Resources
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Related Post
Apr
How You Can Beat the Odds by Getting Screened for Lung Cancer?
Cellular breakdown in the lungs is by a wide margin the deadliest malignant growth for people. The American Malignant growth Society predicts in excess of 230,000 Americans will be analyzed for the current year. Almost 130,000 will bite the dust.
Read MoreApr
Top 10 Health Benefits of Reflexology
Did you realize reflexology is a back rub method that can be followed back to Old Egypt? Here of back rub, the strain is applied in unambiguous regions or zones in the hands and feet that associate to various pieces.
Read MoreMar
The Health Benefits of Deep Breathing (and 4 Easy Techniques!)
Breathing is a characteristic and compulsory activity that occurs for our bodies to take in and discharge air. A necessary activity assists our bodies with working through day to day existence. Breathing assists our respiratory framework with moving oxygen in.
Read MoreMar
10 Yoga Poses to Boost the Immune System
As the days get more limited and temperatures decrease, we might have seen our schedules are advising us that the Christmas season is quick drawing nearer. That additionally implies that cold and influenza season is back! Yet again sadly for.
Read More